Northern Trust Corp lifted its holdings in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 51.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 601,974 shares of the company’s stock after purchasing an additional 204,680 shares during the period. Northern Trust Corp owned 0.99% of Karyopharm Therapeutics worth $10,226,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the company. UBS Group AG boosted its holdings in Karyopharm Therapeutics by 761.8% in the first quarter. UBS Group AG now owns 19,632 shares of the company’s stock valued at $264,000 after acquiring an additional 17,354 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Karyopharm Therapeutics by 38.9% during the second quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $277,000 after purchasing an additional 4,556 shares during the period. Voya Investment Management LLC raised its position in shares of Karyopharm Therapeutics by 24.3% during the second quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock worth $317,000 after purchasing an additional 3,653 shares during the period. California Public Employees Retirement System acquired a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $339,000. Finally, Ardsley Advisory Partners acquired a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $348,000. Institutional investors own 71.21% of the company’s stock.
A number of research firms have recently commented on KPTI. HC Wainwright reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research report on Monday. Wedbush raised Karyopharm Therapeutics from a “neutral” rating to an “outperform” rating and set a $19.00 price target on the stock in a research report on Friday, November 9th. BidaskClub downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 1st. Canaccord Genuity reiterated a “buy” rating and set a $27.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, August 7th. Finally, ValuEngine downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $22.90.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, November 8th. The company reported ($0.79) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.88) by $0.09. Karyopharm Therapeutics had a negative return on equity of 104.50% and a negative net margin of 502.90%. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.21 million. On average, equities analysts forecast that Karyopharm Therapeutics Inc will post -3.04 EPS for the current fiscal year.
In other news, CEO Michael Kauffman sold 9,600 shares of Karyopharm Therapeutics stock in a transaction that occurred on Monday, November 26th. The stock was sold at an average price of $11.00, for a total transaction of $105,600.00. Following the completion of the transaction, the chief executive officer now directly owns 521,743 shares in the company, valued at approximately $5,739,173. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ltd Chione sold 251,468 shares of Karyopharm Therapeutics stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $20.94, for a total value of $5,265,739.92. The disclosure for this sale can be found here. Insiders have sold a total of 493,768 shares of company stock valued at $9,926,611 over the last quarter. 13.26% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2018/12/03/karyopharm-therapeutics-inc-kpti-position-lifted-by-northern-trust-corp.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Recommended Story: Does the discount rate affect the economy?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.